Advanced Catheter Therapies

Advanced Catheter Therapies, Inc. (ACT) is an early stage research and development medical device company with a portfolio of innovative catheter technologies targeting vascular disease including thrombosis, inflammation, occlusions and restenosis.

ACT has initially focused its resources on the problem of restenosis and is developing the game-changing Occlusion Perfusion Catheter™ (OPC™). The OPC is a multi‐lumen balloon catheter designed to temporarily occlude a specific region from blood flow to allow the local delivery of therapeutic agents to the peripheral and coronary vasculature.

Also in the development pipeline are devices to improve endovascular debulking procedures (the clearing of blocked blood vessels).

News

Advanced Catheter Therapies Receives FDA 510(k) Clearance on Occlusion Perfusion Catheter
CHATTANOOGA, TN, October 8, 2013 – Advanced Catheter Therapies, Inc. (ACT), (www.acatheter.com) today announced that its Occlusion Perfusion Catheter™ (OPC) has received U.S. Food and Drug Administration (FDA) 510(k) clearance. ACT is a research and development medical device company with a portfolio of innovative catheter technologies initially targeting vascular disease and restenosis.

“ACT is very excited about the FDA 510(k) approval for the OPC,” said Paul J. Fitzpatrick, CEO of ACT. “It marks a significant advance for ACT and our lead product, and we look forward finding a partner to move the OPC forward to full commercialization. We strongly feel the OPC, which has strong intellectual property and patent protection, is positioned to be the next generation of therapeutic agent delivery devices.”